Versantis

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Versantis is a clinical-stage company developing disruptive orphan drugs for liver and pediatric diseases. Our lead candidate, VS-01, uses a disruptive liposomes-based technology to treat adults with decompensated cirrhosis and/or ACLF effectively (Versantis’ most advanced program), as well as children with rare hyperammonemic crisis caused by genetic disorders. VS-01 is currently being evaluated in first-in-human clinical trials, and Versantis recently closed a USD 16m Series B financing round to advance to Ph2a clinical development. VS-01 was granted two orphan drug designations by the EMA and the FDA, which will streamline its clinical development pathway.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
VS-01
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
Versantis